KR0133544B1
|
|
Human , , t cell antigen receptor polypeptides and nucleic
|
US5976540A
|
|
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
AU2994997A
|
|
Aptamers for complement protein c3b
|
WO9740022A1
|
|
Immunosuppressive compounds from an arylidene diamide array
|
WO9739722A2
|
|
Method of isolating regulators of t cell activation
|
CN1155903A
|
|
T cell antigen receptor V region proteins and methods of preparation thereof
|
US5856300A
|
|
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
WO9426786A1
|
|
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
WO9417822A1
|
|
PULMONARY ADMINISTRATION OF sCR1 AND OTHER COMPLEMENT INHIBITORY PROTEINS
|
US5552300A
|
|
T cell antigen receptor V region proteins and methods of preparation thereof
|
GB9325182D0
|
|
Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
|
WO9414067A1
|
|
Diagnosis and therapy of sarcoidosis
|
US5456909A
|
|
Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
|
US5506247A
|
|
Compounds that inhibit complement and/or suppress immune activity
|
CA2097825A1
|
|
Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
|
US5366986A
|
|
Compounds which inhibit complement and/or suppress immune activity
|
IL108741A
|
|
Monoclonal antibodies reactive with defined regions of the t cell antigen receptor
|
US5223426A
|
|
Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
|
CA2005121A1
|
|
Monoclonal antibodies reactive with defined regions of the t cell antigen receptor
|
AU4416189A
|
|
Therapeutic and diagnostic methods using soluble t cell surface molecules
|